Immuno-Oncology Reports






Immuno-oncology also is known as cancer immunotherapy, describes the process of utilizing the patient's immune system to fight cancer. Immuno-oncology is the cancer treatment with therapies that stimulate or suppress the body's immune system. In the last ten years, immuno-oncology has come up as an exciting approach to cancer treatment due to its specificity, adaptability and durability. One of the main areas within this field is a new class of proteins called immune checkpoints, such as PD-1, which could enable cancer cells to hide from the immune system by modulating T cell signalling. 

Several distinct modalities of Immuno-oncology therapy exist, including bispecific T-cell engaging monoclonal antibodies, cellular immunotherapy and adoptive cellular therapy, cancer vaccines, checkpoint modulating monoclonal antibodies, and oncolytic viruses. 

The immuno-oncology market is expected to reach USD 6 billion by 2024 from USD 3 billion in 2018, at a CAGR of 12% during the forecast period. The growth of this immuno-oncology market is primarily driven by factors such as the increasing adoption of targeted therapy over traditional therapy and increasing demand for monoclonal Antibodies. 

There is a slew of companies like DelveInsight and many others that prepare immuno-oncology reports.  
DelveInsight’s report- "Chimeric Antigen Receptor (CAR) T cell Immunotherapy - Journey from Target to T Cell Product: A Platform to identify Opportunities and Overcome Challenges, 2019", emphasizes on the currently active CAR-T cell products in research and development. The immuno-oncology report provides an in-depth analysis of key market trends and governing factors along with market attractiveness as per segments. The immuno-oncology report also provides the qualitative impact of various market factors on various CAR-T market segments and geographies. The comprehensive insights provided in the immuno-oncology report will help the companies in identifying better opportunities. 

The immuno-oncology report covers the 100+ companies with 270+ CAR-T therapies, which are active in this field, including 50+ clinical companies with 90+ products targeting more than 80+ different antigens and more than 20+ different technologies. 

The immuno-oncology report provides in-depth analysis on the CAR-T cell profiles covering pre-clinical and clinical studies, Collaborations details and Deal values, Technologies and Targeted antigens, Investments and fundings etc. The immuno-oncology report provides the CAR-T licensing opportunities, acquisitions, market drivers and barriers followed by cost-analysis and SWOT Analysis. The report also covers the KOL views on CAR-T Therapy. Additionally, the report covers the comparative analysis of the sales of two approved drugs (Kymriah and Yescarta). The report also describes the unmet needs covered by CAR-T cells highlighting the adverse events, which are significant concerns in the market for the usage of CAR-T cells. The strategists can gain detailed insight and devise appropriate strategies to target a specific market. 




Comments

  1. UnknownFebruary 29, 2020 at 7:19 PM

    Did you know there's a 12 word sentence you can tell your crush... that will trigger intense emotions of love and instinctual attractiveness for you buried within his chest?

    That's because hidden in these 12 words is a "secret signal" that triggers a man's instinct to love, please and care for you with all his heart...

    ====> 12 Words Will Fuel A Man's Desire Impulse

    This instinct is so hardwired into a man's brain that it will drive him to work better than before to make your relationship the best part of both of your lives.

    Matter of fact, fueling this mighty instinct is so mandatory to having the best ever relationship with your man that once you send your man a "Secret Signal"...

    ...You will soon find him open his mind and soul for you in such a way he haven't expressed before and he will perceive you as the only woman in the universe who has ever truly attracted him.

    ReplyDelete

Post a Comment

Popular posts from this blog

Tenosynovial Giant Cell Tumors (TSGCTs) Market Research Report 2030 | Tenosynovial Giant Cell Tumors (TSGCTs) Market

Image
Tenosynovial Giant Cell Tumors   are a type of neoplasm that affects synovial-lined tendon sheaths, synovial joints, and surrounding soft tissue. Locally aggressive benign tissue lesions are defined by synovial lining inflammation in joints and tendons. Overexpression of the colony-stimulating factor 1 receptor is thought to cause these tumors to form. Giant cell tumors of the tendon sheath (GCTTS), pigmented villonodular tumors (PVNTS), extra-articular pigmented villonodular tumors of the tendon sheath, and localized or focal nodular synovitis are all terms used to describe TSGCTs. Tenosynovial Giant Cell Tumors Causes Translocation is an alteration to a chromosome that causes Tenosynovial Giant Cell Tumors. A chromosome segment breaks off and moves around. The cause of these translocations is unknown. The genetic code for making proteins is stored on chromosomes. A protein termed colony-stimulating factor 1 is produced in excess due to the translocation (CSF1). This protein attracts
Read more

Functional Dyspepsia Market Research Report 2030 | Functional Dyspepsia Market

Image
  Functional dyspepsia   is a term for recurring signs and symptoms of indigestion that have no apparent cause. Functional dyspepsia is also called non-ulcer stomach pain or non-ulcer dyspepsia. It's not clear what causes functional dyspepsia. Doctors consider it a functional disorder, which means that routine testing may not show any abnormalities. Hence, it is diagnosed based on symptoms. Functional Dyspepsia Signs and Symptoms  Functional dyspepsia is common and can be long-lasting — although signs and symptoms are mostly intermittent. These signs and symptoms resemble those of an ulcer, discomfort in your upper abdomen, often accompanied by bloating, belching, and nausea, An early feeling of fullness (satiety) when eating, Pain in the stomach that may sometimes occur unrelated to meals, or maybe relieved with meals. Functional Dyspepsia Epidemiology According to an article by Madisch et al. (2018), Functional Dyspepsia is one of the common functional disorders, with a prevalenc
Read more

Fibrodysplasia Ossificans Progressiva Market Research Report 2030 | Fibrodysplasia Ossificans Progressiva Market

Image
  Fibrodysplasia ossificans progressiva   is a disorder in which the skeleton, muscles, and connective tissues, such as tendons and ligaments, are replaced by bone (ossified). This position was to lead to the formation of the bones of the skeleton (extra-skeletal or heterotopic bone) that constrains movement. Fibrodysplasia ossificans progressiva Causes Fibrodysplasia ossificans progressiva is called a mutation in the ACVR1 gene. This gene is involved in bone growth and development. Mutations, and the possibility of a disorderly development. The gene can be inherited from a parent, but in most cases, the, is a new mutation, a person with a less-than-a family history of the disease. As a parent, they have a 50% chance of passing it on to their children. Fibrodysplasia ossificans progressiva Sign and Symptoms The  Fibrodysplasia ossificans progressiva  symptoms begin in the first decade of life with episodes of painful inflammatory soft tissue swellings. Gradually, there occurs restricti
Read more